| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Eton Pharmaceuticals, Inc.$47.83
+1.32 (+2.83%)
Market Cap
892.72 M
EPS
-0.06
P/E Ratio
-
Value Trade
9.06 M
SEC Financials
Q1 2026Dilution Risk
Revenue
24.27 M
R&D Expenses
1.88 M
Operating CF
7.41 M
Total Assets
97.71 M
Total Liabilities
67.09 M
Equity
30.61 M
D/E Ratio
12,345
12.22 %
Week
38.27 %
1 Month
79.46 %
3 Month
99.94 %
6 Month
289.37 %
5 Year
410.02 %
All Time
Cash Data
Cash Position
19.66 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 14, 2026
Overview
Volume
76.35 K
52 Week Range
13.09 - 35.66
% held by Insiders
5.36 %
% held by Institutions
65.15 %
Enterprise Value
904.32 M
Total Shares
27.40 M
Short %
5.14 %
Float Shares
23.87 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Eton Pharmaceuticals, Inc.
474Total events
7Upcoming
237Tier-1 (high impact)
2018 – 2027Coverage
Upcoming catalysts 2
TBD
T2Product Launch
Subscribe to view catalyst details
TBD
T2Trial Initiation
Subscribe to view catalyst details
Event history 2
TBD
◆Topline ReadoutKHINDIVIApprovedClinical Data
Subscribe to view catalyst details
TBD
●sNDA SubmissionKHINDIVIApprovedRegulatory Filing
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-06-30 | KHINDIVI™ (hydrocortisone) Oral Solution | NDA Submission | NDA | — | – | – | – |
2026-06-30 | KHINDIVI™ (hydrocortisone) Oral Solution | NDA Submission | NDA | — | – | – | – |
2026-06-30 | KHINDIVI™ (hydrocortisone) Oral Solution | NDA Submission | NDA | — | – | – | – |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ET-600 | central diabetes insipidus | — | 2025-03-14 | demonstrated pharmacokinetic equivalence to the FDA-approved reference product Read More | Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600 Read More | |
ET-600 | central diabetes insipidus | — | 2025-03-14 | demonstrated pharmacokinetic equivalence to the FDA-approved reference product Read More | Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600 Read More | |
ET-600 | central diabetes insipidus | — | 2025-03-14 | demonstrated pharmacokinetic equivalence to the FDA-approved reference product Read More | Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ETON
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ETON Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ETON▲ +2.8%today
Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral Solution
Eton Pharmaceuticals has submitted a Prior Approval Supplement to the FDA to expand the indication of KHINDIVI (hydrocortisone) oral solution to include younger pediatric patients. The new formulation has demonstrated bioequivalence to ALKINDI SPRINKLE, which could facilitate a broader adoption of the product. If approved, this expansion could significantly benefit children under five years old with adrenal insufficiency.
Read more →ETONEton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)
Eton Pharmaceuticals has secured U.S. commercialization rights for IMPAVIDO® (miltefosine), the only FDA-approved oral treatment for various forms of leishmaniasis. This agreement, effective from September 26, 2026, aligns with Eton's strategy to expand its portfolio of orphan drugs. The company aims to ensure reliable access to this life-saving medication for patients in need.
Read more →ETONEton Pharmaceuticals Reports First Quarter 2026 Financial Results
Eton Pharmaceuticals reported strong financial results for Q1 2026, with product sales reaching $24.3 million, a 73% increase from the previous year. The company raised its revenue guidance for the year to over $120 million, driven by successful product launches including DESMODA and the relaunch of HEMANGEOL. Additionally, Eton initiated a clinical study for ET-700, further expanding its rare disease portfolio.
Read more →ETONEton Pharmaceuticals to Participate in Upcoming Investor Conferences
Eton Pharmaceuticals will participate in three upcoming investor conferences, including the B. Riley Securities Investor Conference, the Craig-Hallum Institutional Investor Conference, and the Jefferies Global Healthcare Conference. These events will enhance the company's visibility and engagement with investors. Eton focuses on developing treatments for rare diseases and has a robust product pipeline.
Read more →ETONEton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
Eton Pharmaceuticals will report its first quarter 2026 financial results on May 14, 2026. A conference call and live audio webcast will be held at 4:30 p.m. ET to discuss the results. Investors can submit questions via email, and an archived version of the webcast will be available for 30 days post-event.
Read more →ETON▲ +19.8%on this newsshared move
Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution
Eton Pharmaceuticals has relaunched HEMANGEOL®, the sole FDA-approved treatment for infantile hemangiomas, through Anovo Specialty Pharmacy. The company has integrated Eton Cares patient support, offering $0 co-pay for eligible patients. This initiative aims to facilitate quick access to therapy, crucial for improving outcomes in infants requiring treatment for this rare disease.
Read more →ETONEton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700
Eton Pharmaceuticals has initiated a pilot clinical study for ET-700, a new formulation aimed at treating Wilson disease. The first patient has been dosed, and results are anticipated in late 2026. If successful, a pivotal study could follow in early 2027, with significant market potential projected for the treatment.
Read more →ETON▼ -9.4%on this news
Eton Pharmaceuticals Announces CFO Succession Plan
Eton Pharmaceuticals has announced Judith Matthews as the new CFO, effective June 1, 2026, succeeding James Gruber. Gruber will assist in the transition through a consulting agreement. Matthews, with extensive experience in finance for pharmaceutical companies, aims to support Eton's growth in the rare disease sector.
Read more →ETON▲ +7.5%on this news
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
Eton Pharmaceuticals reported impressive financial results for Q4 2025, achieving $21.3 million in product sales, an 83% increase from the previous year. The company launched three major products in 2025 and anticipates further growth with the recent FDA approval of DESMODA and the acquisition of HEMANGEOL. Eton expects to exceed $110 million in revenue for 2026, marking a significant milestone in its growth trajectory.
Read more →ETONEton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026
Eton Pharmaceuticals will report its fourth quarter and full year 2025 financial results on March 19, 2026. Management will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the results and answer questions from investors. The company is known for its focus on developing treatments for rare diseases.
Read more →ETON▲ +6.8%on this newsshared move
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution
Eton Pharmaceuticals has acquired U.S. commercialization rights to HEMANGEOL, the only FDA-approved treatment for infantile hemangiomas requiring systemic therapy. This acquisition aligns with Eton's focus on rare diseases and will be supported by their Eton Cares patient program, which includes a $0 co-pay initiative. The transaction is anticipated to positively impact Eton's earnings in 2026.
Read more →ETONEton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution
Eton Pharmaceuticals has received FDA approval for DESMODA, an oral solution of desmopressin acetate, aimed at managing central diabetes insipidus. This formulation is the first of its kind, designed for precise dosing across all ages. Eton anticipates significant sales potential and aims to enhance treatment management for patients with this rare condition.
Read more →ETONEton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th
Eton Pharmaceuticals will participate in the Leerink Partners Global Healthcare Conference on March 11, 2026, in Miami, Florida. The company's executive leadership team will host one-on-one meetings during the event. Eton is focused on developing treatments for rare diseases and has several commercial products and candidates in late-stage development.
Read more →ETONEton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate
Eton Pharmaceuticals has announced the licensing of U.S. marketing rights for a product candidate aimed at treating an ultra-rare disease. This product is anticipated to be the first generic alternative for a condition affecting fewer than 100 patients in the U.S. The company plans to launch the product in mid-2026, enhancing its portfolio of rare disease treatments.
Read more →ETONEton Pharmaceuticals to Present at Piper Sandler 37th Annual Healthcare Conference on December 4th
Eton Pharmaceuticals announced its participation in the Piper Sandler 37th Annual Healthcare Conference scheduled for December 4, 2025, in New York City. Members of the executive leadership team will host a fireside chat, providing an opportunity for investors to engage with the company. Eton is dedicated to developing treatments for rare diseases, with multiple commercial products and candidates in late-stage development, highlighting its commitment to innovation in the pharmaceutical space.
Read more →ETONEton Pharmaceuticals to Participate at 16th Annual Craig-Hallum Alpha Select Conference on November 18th
Eton Pharmaceuticals will participate in the 16th Annual Craig-Hallum Alpha Select Conference on November 18, 2025. The company's executive leadership team will host one-on-one meetings during the event. Eton specializes in developing treatments for rare diseases and has several products currently on the market and in development.
Read more →ETON▼ -11.7%on this newsshared move
Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results
Eton Pharmaceuticals reported a strong third quarter for 2025, with product sales increasing by 129% year over year, driven by growth in ALKINDI SPRINKLE and Carglumic Acid. The company also announced that its NDA for ET-600 has been accepted by the FDA, with a target action date of February 25, 2026. Despite the positive sales growth, Eton reported a net loss for the quarter, attributed to rising general and administrative expenses.
Read more →ETONEton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
Eton Pharmaceuticals announced it will report its third quarter 2025 financial results on November 6, 2025. The management team will hold a conference call and live audio webcast at 4:30 p.m. ET to discuss the results and take live questions. Eton is known for focusing on treatments for rare diseases and currently has eight commercial products and five product candidates in late-stage development.
Read more →ETONEton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference
Eton Pharmaceuticals announced its participation in the 2025 Wells Fargo Healthcare Conference, scheduled for September 3-5, 2025, in Boston, MA. Members of Eton's executive leadership team will conduct one-on-one meetings with investors during the event. The company specializes in treatments for rare diseases and has a robust portfolio of products.
Read more →ETONEton Pharmaceuticals Reports Second Quarter 2025 Financial Results
Eton Pharmaceuticals reported impressive second quarter 2025 financial results, achieving $18.9 million in product sales, representing a 108% increase from the same period last year. The company launched KHINDIVI, the first FDA-approved oral hydrocortisone solution, and projected an annual revenue run rate of $80 million for Q3, exceeding prior guidance. Despite a positive outlook, the company reported a GAAP EPS of $(0.10) and increased R&D and G&A expenses. Eton's continued growth is supported by strong sales figures and robust engagement with the healthcare community.
Read more →ETONEton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025
Eton Pharmaceuticals, a company dedicated to developing treatments for rare diseases, will report its financial results for the second quarter of 2025 on August 7, 2025. A live audio webcast and conference call will be held at 4:30 p.m. ET to discuss these results and answer questions from investors. Eton currently markets eight products for rare diseases and has additional candidates in late-stage development, signifying ongoing innovation in their pipeline.
Read more →ETON▲ +9.8%on this news
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)
Eton Pharmaceuticals has announced that the FDA has accepted its New Drug Application for ET-600, a desmopressin oral solution. The drug is aimed at treating central diabetes insipidus in pediatric patients and has been assigned a target action date of February 25, 2026. Eton's CEO expressed optimism about the drug's potential to meet significant unmet needs in the market.
Read more →ETONEton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes
Eton Pharmaceuticals has announced its inclusion in the Russell 2000 and Russell 3000 indexes, effective after market close on June 27, 2025. This addition is seen as a significant milestone for the company, reflecting the shareholder value generated over the past year. Eton aims to enhance its visibility among investors while continuing to develop treatments for rare diseases.
Read more →ETON▼ -5.8%on this news
Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydrocortisone) Oral Solution
Eton Pharmaceuticals has received FDA approval for KHINDIVI, the first oral hydrocortisone solution for pediatric patients with adrenocortical insufficiency. The product is designed for easy dosing and is expected to launch commercially by June 2nd. Eton anticipates significant sales growth, projecting combined peak sales of KHINDIVI and ALKINDI SPRINKLE to exceed $50 million annually.
Read more →ETON▲ +15.1%on this news
Eton Pharmaceuticals to Participate at Upcoming Investor Conferences
Eton Pharmaceuticals announced participation in two upcoming investor conferences, featuring CEO Sean Brynjelsen, CFO James Gruber, and CBO David Krempa. The company focuses on treatments for rare diseases and has a strong portfolio of commercial products and late-stage candidates. No webcasts will be available for these events.
Read more →ETONEton Pharmaceuticals Reports First Quarter 2025 Financial Results
Eton Pharmaceuticals reported strong financial results for Q1 2025, with revenues reaching $17.3 million, marking a 76% increase year-over-year. The company has successfully relaunched INCRELEX and GALZIN, contributing to its growing sales momentum. Additionally, Eton is preparing for the anticipated launch of ET-400 and has submitted an NDA for ET-600, highlighting its commitment to advancing treatments for rare diseases. Management expressed confidence in sustaining growth throughout the year with several new product launches planned.
Read more →ETONEton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025
Eton Pharmaceuticals announced it will report its first quarter 2025 financial results on May 13, 2025. Management will host a conference call and webcast to discuss the results and engage with investors through questions. The company remains focused on developing and commercializing treatments for rare diseases, highlighting its array of current commercial products and late-stage candidates.
Read more →ETONEton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)
Eton Pharmaceuticals has announced the submission of a New Drug Application (NDA) for ET-600, an oral solution of desmopressin aimed at treating central diabetes insipidus. The FDA is expected to review the application within 10 months, with plans for a launch in the first quarter of 2026 if approved. This potential product is significant as it would be the only FDA-approved oral liquid formulation, fulfilling a need expressed by pediatric endocrinologists. The company is already proceeding with commercial preparations ahead of the anticipated approval.
Read more →ETONEton Pharmaceuticals Out-Licenses International Rights to Increlex
Eton Pharmaceuticals has announced the out-licensing of commercial rights to its product Increlex® to Esteve Pharmaceuticals for territories outside the U.S. This partnership is expected to enhance the distribution of Increlex globally while allowing Eton to concentrate on developing its products within the U.S. market. Esteve will manage the international commercialization efforts, minimizing the need for Eton to invest in significant infrastructure. This agreement also does not change Eton's projected revenue expectations for 2025.
Read more →ETONEton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
Eton Pharmaceuticals reported its fourth quarter 2024 financial results, showcasing record product revenue of $11.6 million, marking a 59% increase from the previous year. The company successfully relaunched the pediatric product Increlex and also acquired and relaunched Galzin, leading to significant growth. Additionally, Eton announced positive results from a pivotal clinical study for ET-600, with plans for a New Drug Application submission in April 2025. Overall, the results reflect Eton's commitment to expanding its portfolio in pediatric endocrinology and rare diseases.
Read more →ETON▲ +6.7%on this newsshared move
Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600
Eton Pharmaceuticals announced positive results from a pivotal bioequivalence study of its oral solution ET-600 for treating central diabetes insipidus. The study demonstrated pharmacokinetic equivalence to the FDA-approved reference product. Following these results, the company plans to submit a New Drug Application (NDA) in April 2025 and has initiated pre-launch activities in anticipation of a potential market entry in early 2026. ET-600 aims to meet the specific dosing needs of pediatric patients suffering from this condition.
Read more →ETONEton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025
Eton Pharmaceuticals announced it will host a virtual Investor Day on March 18, 2025, where it will report its fourth quarter 2024 financial results. The event will offer insights into Eton's rare disease treatments and its financial outlook after a pivotal six months. Key executives will participate in discussions about their product portfolio, including recently acquired products and updates on current developments. The presentation will also include a Q&A session for audience interaction.
Read more →ETONEton Pharmaceuticals Announces Commercial Launch of Galzin (zinc acetate) Capsules
Eton Pharmaceuticals has launched Galzin (zinc acetate) capsules, the only FDA-approved zinc therapy for Wilson disease, aimed at improving patient access. The medication is available through Optime Care, which will also manage the Eton Cares Program, providing support for eligible patients, including a $0 co-pay. Eton is dedicated to enhancing treatment access and is investing in further research for Wilson disease. Due to some safety concerns, close monitoring of patients on Galzin is advised, particularly regarding potential copper deficiency and gastric ulcers.
Read more →ETONEton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600
Eton Pharmaceuticals has announced the issuance of a new U.S. patent for ET-600, its proprietary formulation of desmopressin oral solution, which is aimed at treating diabetes insipidus. The patent, granted by the USPTO, extends protection until 2044 and is expected to be listed in the FDA's Orange Book upon approval. The ET-600 product is particularly significant as it addresses the needs of pediatric patients, who currently lack FDA-approved oral liquid formulations of desmopressin. Eton anticipates filing a New Drug Application with the FDA in the second quarter of 2025, pending positive results from an ongoing pivotal bioequivalence study.
Read more →ETONEton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400
Eton Pharmaceuticals has announced that the FDA has extended the PDUFA goal date for its New Drug Application (NDA) for ET-400 to May 28, 2025. This standard three-month extension enables the FDA to conduct a more comprehensive review based on supplemental information provided by Eton. Despite the extension, Eton's CEO expressed confidence in their NDA submission and does not expect it to affect their revenue projections for 2025.
Read more →ETON▼ -9.2%on this news
Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin
Eton Pharmaceuticals has announced the acquisition of Galzin, an FDA-approved treatment for Wilson Disease, an ultra-rare metabolic condition. This acquisition aligns with Eton's commitment to providing life-saving treatments for rare diseases and will be supported by the company's Eton Cares program to assist patients with access to the medication. Eton plans to commercialize Galzin in the United States in early 2025 and continues to hold distribution rights in European markets. The company emphasizes its dedication to addressing the needs of this small patient population through personalized support services.
Read more →ETONEton Pharmaceuticals Closes Acquisition of Increlex (mecasermin injection)
Eton Pharmaceuticals has finalized its acquisition of Increlex, a biologic used to treat pediatric patients with severe primary insulin-like growth factor 1 deficiency (SPIGFD). Increlex is now available in the U.S. through AnovoRx, enhancing Eton's portfolio in pediatric endocrinology. The product is the only FDA-approved treatment for SPIGFD, which is currently underdiagnosed. Eton plans to leverage its existing sales force to raise awareness and improve access for patients requiring this treatment.
Read more →ETONEton Pharmaceuticals Announces Final Readout of PKU GOLIKE Clinical Trial
Eton Pharmaceuticals announced the final results of the clinical trial for its product PKU GOLIKE, a protein substitute for patients with phenylketonuria (PKU). The study revealed that PKU GOLIKE significantly improved metabolic control during prolonged fasting, showing a marked reduction in harmful phenylalanine (Phe) levels and an increase in beneficial tyrosine (Tyr) levels compared to standard amino acid substitutes. These findings indicate a promising future for PKU GOLIKE in clinical practice and PKU management. The company anticipates that these results will enhance adoption among healthcare professionals and patients alike.
Read more →ETON▼ -5.1%on this news
Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer
Eton Pharmaceuticals has appointed Ipek Erdogan-Trinkaus as the new Chief Commercial Officer. With significant experience in the pharmaceutical industry, particularly in pediatric endocrinology, she aims to lead the company's upcoming product launches, including Increlex and ET-400. The CEO expressed strong confidence in her ability to enhance Eton's commercial operations and drive growth. Eton continues to focus on developing treatments for rare diseases.
Read more →ETON▲ +7.1%on this news· ran to +20% by day 3
Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)
Eton Pharmaceuticals, Inc. has announced its acquisition of the U.S. rights to Amglidia (glyburide oral suspension), intended for treating neonatal diabetes mellitus. The acquisition aligns with Eton's focus on pediatric endocrinology and addresses a significant market need in the U.S., where no FDA-approved oral treatments currently exist for this condition. The product has gained successful traction in Europe and holds Orphan Drug Designation in the U.S., paving the way for Eton to submit a New Drug Application in 2026. This strategic move is seen as a crucial enhancement to Eton's portfolio.
Read more →ETON▼ -5.6%on this news
Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results
Eton Pharmaceuticals has reported a strong third quarter for 2024, achieving total revenues of $10.3 million and marking its first positive GAAP net income. The company's product sales grew by 40% year-over-year, supported by successful sales of ALKINDI SPRINKLE and Carglumic Acid. Eton also entered an asset purchase agreement to acquire Increlex, a move expected to enhance its commercial portfolio. Additionally, the FDA accepted the New Drug Application for ET-400, with a target action date set for February 2025, indicating potential future market growth.
Read more →ETONEton Pharmaceuticals Awarded Second Patent for ET-400 (Hydrocortisone Oral Solution)
Eton Pharmaceuticals, Inc. has been awarded a second patent for ET-400, a liquid formulation of hydrocortisone, which will be protected until 2043. This product aims to meet the needs of patients requiring an FDA-approved liquid form of hydrocortisone. The FDA has accepted Eton's New Drug Application for ET-400, with a target action date scheduled for February 28, 2025. The company's CEO expressed optimism about the patent grant, indicating the product's significance in the market.
Read more →ETONEton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Eton Pharmaceuticals, Inc. has announced it will report its third quarter 2024 financial results on November 12, 2024. The company will host a conference call at 4:30 p.m. ET to discuss these results. Investors will have the opportunity to ask questions during the call or submit inquiries via email. Eton specializes in developing treatments for rare diseases and currently markets five products while having additional candidates in late-stage development.
Read more →ETON▲ +16.3%on this news
Eton Pharmaceuticals, Inc to Acquire Increlex (mecasermin injection) from Ipsen
Eton Pharmaceuticals, Inc has announced its acquisition of Increlex (mecasermin injection) from Ipsen S.A., a move that aligns with its mission to support patients with ultra-rare conditions. The acquisition, expected to close by the end of 2024, will bolster Eton's pediatric endocrinology portfolio, as Increlex is a critical treatment for severe IGF-1 deficiency in children. Eton plans to commercialize Increlex in the U.S. immediately post-acquisition, with Ipsen managing distribution in other territories during a transitional period.
Read more →ETONEton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
Eton Pharmaceuticals, a company focused on rare disease treatments, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference in New York City. CEO Sean Brynjelsen will present on September 9, 2024, with the session available on demand. This conference serves as a platform for Eton to connect with investors and share insights into its innovative product pipeline.
Read more →ETONEton Pharmaceuticals Reports Second Quarter 2024 Financial Results
Eton Pharmaceuticals reported its Q2 2024 financial results, highlighting a 40% increase in product sales to $9.1 million compared to the same quarter in 2023. The company's NDA for ET-400 has been accepted by the FDA with a PDUFA date of February 28, 2025. Eton also showcased significant growth from its existing products, particularly ALKINDI SPRINKLE and Carglumic Acid. Despite reporting a net loss of $2.9 million during the quarter, the firm remains optimistic about future growth driven by its ongoing pipeline initiatives.
Read more →ETONEton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
Eton Pharmaceuticals announced it will report its second quarter 2024 financial results on August 8, 2024. Management will host a conference call and live audio webcast at 4:30 p.m. ET to discuss these results and answer questions from investors. The company specializes in developing treatments for rare diseases and has five commercial products along with three candidates in late-stage development. This proactive reporting indicates ongoing business activity and engagement with investors.
Read more →ETONEton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
Eton Pharmaceuticals announced the FDA's acceptance of its New Drug Application (NDA) for ET-400, a proprietary hydrocortisone oral solution, with a PDUFA action date set for February 28, 2025. The company anticipates that upon approval, ET-400 will enable it to secure a larger market share in oral hydrocortisone, possibly reaching combined peak sales of over $50 million annually when combined with existing products. Additionally, ET-400 is protected by a patent valid until 2043, enhancing its market potential. Eton aims for a potential product launch in early 2025.
Read more →ETON▼ -7.7%on this news
Eton Pharmaceuticals Reports First Quarter 2024 Financial Results
Eton Pharmaceuticals reported a successful first quarter for 2024, achieving a revenue of $8.0 million, which represents a 50% increase compared to the same quarter last year. This marks the company's 13th consecutive quarter of growth in product sales. Noteworthy developments include the acquisition of PKU GOLIKE, the launch of Nitisinone, and the submission of a New Drug Application for ET-400, with the potential for its approval in early 2025. The company anticipates continued growth driven by its expanding portfolio and strong sales momentum.
Read more →ETON▲ +5.1%on this news
Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
Eton Pharmaceuticals, Inc., an innovative company specializing in treatments for rare diseases, will present at the Citizens JMP Life Sciences Conference on May 13, 2024. The presentation will be led by CEO Sean Brynjelsen and CFO James Gruber. Eton currently has several commercial products and additional candidates in late-stage development, signaling its commitment to advancing healthcare for rare conditions.
Read more →ETONEton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
Eton Pharmaceuticals has announced the submission of a New Drug Application (NDA) to the FDA for ET-400, a hydrocortisone oral solution. The company expects a review period of approximately 10 months, with potential approval and market launch slated for the first quarter of 2025. Eton anticipates that ET-400, along with its existing product Alkindi Sprinkle, could generate combined peak sales exceeding $50 million annually. Additionally, the product is backed by patent protection that lasts until 2043.
Read more →ETONEton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
Eton Pharmaceuticals has announced that it will report its first quarter 2024 financial results on May 9, 2024. Management will host a conference call at 4:30 p.m. ET to discuss the results and answer questions from investors. Eton continues to focus on developing and commercializing treatments for rare diseases, with several products in both commercial use and late-stage development. Details for accessing the live webcast and registration for the conference call have been provided in the announcement.
Read more →ETON▲ +9.4%on this news
Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE for Phenylketonuria
Eton Pharmaceuticals has acquired U.S. rights to PKU GOLIKE, a specialized medical formula for the treatment of phenylketonuria (PKU) from Relief Therapeutics. The acquisition is anticipated to enhance Eton's earnings in 2024, with expected peak sales of over $10 million annually. PKU GOLIKE, which utilizes innovative technology for better taste and delayed amino acid release, aims to serve the 8,000 PKU patients in the U.S. The partnership seeks to leverage Eton's existing metabolic sales force to boost product awareness in a market valued at $100 million annually.
Read more →ETONEton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
Eton Pharmaceuticals reported strong financial results for Q4 and full year 2023, with revenues reaching $31.6 million and experiencing a 109% increase from the prior year in Q4. The company achieved a twelfth consecutive quarter of sequential sales growth, primarily driven by its products ALKINDI SPRINKLE and Carglumic Acid. Additionally, positive developments were announced regarding their pipeline products ET-400 and ET-600, with NDA submissions planned for 2024. Despite the positive trends, Eton also reported a net loss and increasing operational costs in the last quarter.
Read more →ETONEton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024
Eton Pharmaceuticals, a company focused on developing treatments for rare diseases, will report its fourth quarter and full year 2023 financial results on March 14, 2024. Following the announcement, management will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the results with investors. The company currently has several FDA-approved products and is advancing additional product candidates in development.
Read more →ETONEton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation
Eton Pharmaceuticals announced that it has received a U.S. patent for its proprietary oral liquid formulation of hydrocortisone, specifically for product candidate ET-400. The patent, set to expire in 2043, will be included in the FDA's Orange Book once the product gains approval. This patent marks a significant milestone for Eton, which also has multiple products approved for rare diseases and is in the late stages of developing additional candidates.
Read more →ETONEton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules
Eton Pharmaceuticals has announced the commercial availability of Nitisinone Capsules for the treatment of hereditary tyrosinemia type 1 (HT-1). This ultra-rare disease impacts fewer than 500 patients in the U.S., and the product is expected to serve a significant patient base. Nitisinone will be available through Optime Care, which will also administer the Eton Cares patient support program, providing $0 co-pays for eligible patients. The total market for Nitisinone is estimated to exceed $50 million annually, signaling strong growth potential for Eton Pharmaceuticals.
Read more →ETONEton Pharmaceuticals Reports Third Quarter 2023 Financial Results
Eton Pharmaceuticals reported strong financial results for Q3 2023, achieving $7.0 million in product sales and royalty revenue, marking an increase of 118% from the previous year. The company also noted positive cash flow from operations and an increase in cash on hand to $22.1 million. Eton acquired Nitisinone Capsules, its fourth commercial product, which is expected to be launched in early 2024. Management expressed optimism about continued growth, driven by strong sales of existing products and upcoming product launches.
Read more →ETONEton Pharmaceuticals to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
Eton Pharmaceuticals, Inc. has announced the timing for its third quarter 2023 financial results, set to be released on November 9, 2023. The company will host a conference call and live audio webcast to discuss these results, allowing investor questions to be addressed both live and via email. Eton focuses on developing and commercializing products for rare diseases, with several FDA-approved treatments and additional candidates in late-stage development.
Read more →ETONEton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone
Eton Pharmaceuticals has announced its acquisition of Nitisinone Capsules through a bankruptcy proceeding, with the transaction expected to finalize on October 12, 2023. Nitisinone, FDA-approved for treating hereditary tyrosinemia type 1, represents an additional rarity-focused product for Eton, as the company aims to introduce it to the market in the first quarter of 2024. Eton estimates that the Nitisinone market could exceed $50 million annually. The company also plans to provide a patient support program, strengthening its commitment to those with rare diseases.
Read more →ETONEton Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Eton Pharmaceuticals, a company dedicated to developing treatments for rare diseases, will be presenting at the H.C. Wainwright 25th Annual Global Investment Conference in New York City on September 13, 2023. CEO Sean Brynjelsen will be the speaker, emphasizing Eton's commitment to innovation in the pharmaceutical industry. The company currently offers several products for rare diseases and has multiple candidates in late-stage development, showcasing its active role in addressing unmet medical needs.
Read more →ETONEton Pharmaceuticals Reports Second Quarter 2023 Financial Results Total Q2 revenue of $12.0 million and net income of $4.6 million Product sales and royalty revenue of $6.5 million up 175% from Q2 2022 and 22% from Q1 2
Eton Pharmaceuticals reported strong financial results for the second quarter of 2023, with total revenue reaching $12.0 million, a significant increase from the previous year. The company experienced a 175% rise in product sales and royalty revenue, attributed to the success of ALKINDI SPRINKLE and Carglumic Acid. Eton launched Betaine Anhydrous, which has gained positive traction, and aims to expand its product offerings with a projected NDA submission for its candidate ET-400 by Q4 2023. The company continues to improve its financial position, ending the quarter with $21.6 million in cash reserves.
Read more →ETONEton Pharmaceuticals to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
Eton Pharmaceuticals, Inc. will report its second quarter 2023 financial results on August 10, 2023. A conference call and live audio webcast will be held at 4:30 p.m. ET to discuss the results, where management will also engage with investors through live questions and emails. The company is actively developing treatments for rare diseases and currently has three FDA-approved products.
Read more →ETON▼ -17.3%on this news
Eton Pharmaceuticals Receives Complete Response Letter (CRL) for Dehydrated Alcohol Injection
Eton Pharmaceuticals has received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application for dehydrated alcohol injection aimed at treating methanol poisoning. The concerns raised by the FDA primarily revolve around Chemistry Manufacturing and Controls (CMC). Despite this setback, Eton's CEO expressed confidence that the issues are addressable and emphasized the company's ongoing strength in commercial business and product revenue growth. Eton is also expanding its product portfolio with the recent addition of Betaine Anhydrous for Oral Solution.
Read more →ETONEton Pharmaceuticals Reports First Quarter 2023 Financial Results Product sales and royalty revenue of $5.3 million up 144% from Q1 2022 and 52% from Q4 2022 Launched Betaine Anhydrous Management to hold conference call
Eton Pharmaceuticals reported a robust first quarter for 2023, demonstrating a 144% increase in product sales and royalty revenue, reaching $5.3 million. The company has launched Betaine Anhydrous and boasts strong performances from existing products like ALKINDI SPRINKLE and Carglumic Acid, facilitated by an expanded sales force. Although net losses were reduced compared to the previous year, G&A expenses have risen. Management remains optimistic about future profitability and growth.
Read more →ETONEton Pharmaceuticals Announces Commercial Availability of Betaine Anhydrous for Oral Solution - Eton Cares patient support program offers $0 co-pay to eligible, commercially insured patients* - - Product is now available
Eton Pharmaceuticals has announced the commercial availability of Betaine Anhydrous for Oral Solution, aimed at treating homocystinuria. This new product is positioned as a cost-effective alternative to Cystadane and is available exclusively through Optime Care, which will also provide patient support services. The Eton Cares program offers a $0 co-pay option for eligible patients, enhancing access to treatment. However, the product may pose risks for patients with CBS deficiency, potentially worsening certain medical conditions.
Read more →ETONEton Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
Eton Pharmaceuticals, Inc. has announced a date to report its first quarter financial results for 2023, scheduled for May 11. The company will host a conference call and live audio webcast to discuss these results, allowing participant interaction through live and emailed questions. Eton focuses on developing treatments for rare diseases and currently has three FDA-approved products and several candidates in the pipeline.
Read more →ETON▲ +7.9%on this news
Eton Pharmaceuticals Reports Fourth Quarter 2022 Financial Results Q4 2022 revenue of $8.5 million Q4 Product sales and royalty revenue up 220% from prior year and 9% from Q3 Q4 positive net income Management to hold con
Eton Pharmaceuticals reported financial results for Q4 2022, achieving revenues of $8.5 million, a 220% increase from the previous year. The company noted a positive net income and has expanded its sales force to support ongoing and upcoming product launches. Despite some setbacks due to seasonal factors that affected product sales, Eton's management expressed optimism for continued growth through 2023 and beyond, with targeted launches for new treatment products. The firm also highlighted increased adoption of Carglumic Acid and ALKINDI SPRINKLE as contributing factors to their financial success.
Read more →ETONEton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600 - Product is targeting a rare pediatric endocrinology condition - - Potential for NDA submission in Q2 2024
Eton Pharmaceuticals has announced its acquisition of ET-600, a rare disease product candidate aimed at treating a specific pediatric endocrinology condition impacting fewer than 5,000 patients in the U.S. The company plans to submit a New Drug Application (NDA) to the FDA by the second quarter of 2024, with potential approval and market launch expected in early 2025. This acquisition aligns with Eton’s strategy in rare diseases and could significantly enhance its product portfolio and revenue stream.
Read more →ETONEton Pharmaceuticals to Report Fourth Quarter 2022 Financial Results on Thursday, March 16, 2023
Eton Pharmaceuticals, Inc. announced that it will report its fourth quarter 2022 financial results on March 16, 2023. The company will host a conference call and webcast at 4:30 p.m. ET to discuss these results, during which management will address live and emailed questions from participants. Eton currently has three FDA-approved products and is working on three late-stage pipeline candidates.
Read more →ETON▲ +13.8%on this news
Eton Pharmaceuticals Announces FDA Acceptance of NDA Response for Dehydrated Alcohol Injection - Product previously granted orphan drug designation for methanol poisoning - - Application assigned a PDUFA date of
Eton Pharmaceuticals announced that the FDA has accepted its New Drug Application response for dehydrated alcohol injection, intended for treating methanol poisoning. This product has received orphan drug designation and is on track for a potential market launch by June 27, 2023. The company's CEO expressed optimism about bringing the product to patients, highlighting the urgent need for the treatment.
Read more →ETONEton Pharmaceuticals Reports Third Quarter 2022 Financial Results
Pharmaceuticals Reports Third Quarter 2022 Financial Results PARK, Ill., November 10, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare
Read more →ETONEton Pharmaceuticals to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022
DEER PARK, Ill., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2022 financial results on T
Read more →ETONEton Pharmaceuticals to Present at the LD Micro Main Event XV Conference
DEER PARK, Ill., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that Sean Brynjelsen, Chief Executive Off
Read more →ETONEton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution -- Expected to be accretive to 2023 earnings
Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution -- Expected to be accretive to 2023 earnings -- PARK, Illinois - September 13, 2022 - Eton Pharmaceuticals ("Eton" or "the Company") (Nasdaq: ETON), an innovative ph
Read more →ETONEton Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
DEER PARK, Ill., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that Sean Brynjelsen, Chief Executive Off
Read more →ETONEton Pharmaceuticals Reports Second Quarter 2022 Financial Results
Pharmaceuticals Reports Second Quarter 2022 Financial Results PARK, Ill., August 11, 2022 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported fin
Read more →ETONEton Pharmaceuticals to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022
DEER PARK, Ill., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2022 financial results on
Read more →ETON▲ +8.6%on this news
Eton Pharmaceuticals Announces FDA Approval of ZONISADE™ (Zonisamide Oral Suspension)
DEER PARK, Ill., July 18, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved
Read more →ETONEton Pharmaceuticals Announces Sale of Hospital Products Eton sold its rights in Biorphen , Rezipres , and Cysteine Hydrochloride products for total payments of up to $50 million Going forward, Eton's commercial portfoli
Pharmaceuticals Announces Sale of Hospital Products Eton sold its rights in Biorphen , Rezipres , and Cysteine Hydrochloride products for total payments of up to $50 million Going forward, Eton's commercial portfolio will exclusively focus on products that treat rare disease
Read more →ETON▼ -5.9%on this news
Eton Pharmaceuticals Reports First Quarter 2022 Financial Results
Eton Pharmaceuticals Reports First Quarter 2022 DEER PARK, Ill., May 12, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial res
Read more →ETONEton Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
DEER PARK, Ill., May 03, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2022 financial results on Thu
Read more →ETON▼ -10.4%on this news
Eton Pharmaceuticals Announces FDA Approval of Cysteine Hydrochloride Injection
Eton Pharmaceuticals Announces FDA Approval of Cysteine Hydrochloride Injection DEER PARK, Ill., April 11, 2022 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare dise
Read more →ETON▼ -10.4%on this news
Eton Pharmaceuticals Appoints James Gruber as Chief Financial Officer
Pharmaceuticals Appoints James Gruber as Chief Financial Officer PARK, Ill., April 11, 2022 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced
Read more →ETONEton Pharmaceuticals Reports Fourth Quarter 2021 Financial Results - Fourth Quarter 2021 Revenue of $6.1 million - Fourth Quarter 2021 Net Income of $1.0 million and EPS of $0.04
Pharmaceuticals Reports Fourth Quarter 2021 Financial Results - Fourth Quarter 2021 Revenue of $6.1 million - Fourth Quarter 2021 Net Income of $1.0 million and EPS of $0.04 PARK, Ill., Mar. 16, 2022 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative p
Read more →ETONEton Pharmaceuticals and XGen Pharmaceuticals DJB Announce Commercial Launch of Rezipres (ephedrine hydrochloride), a Ready-to-Use Formulation of Injectable Ephedrine (4.7 mg/mL)
Pharmaceuticals and XGen Pharmaceuticals DJB Announce Commercial Launch of Rezipres (ephedrine hydrochloride), a Ready-to-Use Formulation of Injectable Ephedrine (4.7 mg/mL) PARK, Ill., Mar. 14, 2022 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc. (Nasdaq: ETON) and XGen Pharmace
Read more →ETONEton Pharmaceuticals to Report Fourth Quarter 2021 Financial Results on Wednesday, March 16, 2022
DEER PARK, Ill., March 08, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter 2021 financial results on
Read more →ETONEton Pharmaceuticals and ANI Pharmaceuticals Announce Commercial Availability of Carglumic Acid Tablets, the First and Only FDA-Approved Generic Version of Carbaglu (carglumic acid) Product is now available exclusively t
Pharmaceuticals and ANI Pharmaceuticals Announce Commercial Availability of Carglumic Acid Tablets, the First and Only FDA-Approved Generic Version of Carbaglu (carglumic acid) Product is now available exclusively through Anovo specialty pharmacy Product is stable at room t
Read more →ETONEton Pharmaceuticals Reports Third Quarter Financial Results
Pharmaceuticals Reports Third Quarter Financial Results PARK, Ill., Nov. 15, 2021 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial r
Read more →ETONEton Pharmaceuticals Announces Co-Promotion Agreement with Tolmar Pharmaceuticals for ALKINDI SPRINKLE - Tolmar's 62-person sales force will co-promote ALKINDI SPRINKLE to pediatric endocrinologists
Pharmaceuticals Announces Co-Promotion Agreement with Tolmar Pharmaceuticals for ALKINDI SPRINKLE Tolmar's 62-person sales force will co-promote ALKINDI SPRINKLE to pediatric endocrinologists - PARK, Ill., Nov. 15, 2021 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (Nasdaq: ETON
Read more →ETON▼ -10.7%on this news· ran to -23% by day 3
Eton Pharmaceuticals and Azurity Pharmaceuticals, Inc. Announce FDA Approval of EPRONTIA™ (topiramate) Oral Solution
DEER PARK, Ill. and WOBURN, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON) and Azurity Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved EPRONTIA™ (topiramate) oral solution, 25mg/mL. EPRONTIA™
Read more →ETON▼ -10.7%on this news· ran to -23% by day 3
Eton Pharmaceuticals, Inc. and Azurity Pharmaceuticals, Inc. Announce FDA Approval of EPRONTIA (topiramate) oral solution The first and only FDA-approved ready-to-use liquid topiramate DEER PARK, Ill, and WOBURN, MA
Pharmaceuticals, Inc. and Azurity Pharmaceuticals, Inc. Announce FDA Approval of EPRONTIA (topiramate) oral solution first and only FDA-approved ready-to-use liquid topiramate PARK, Ill, and WOBURN, MA, Nov. 8, 2021 (GLOBE NEWSWIRE)-Eton Pharmaceuticals, Inc (Nasdaq: ETON) and
Read more →ETONEton Pharmaceuticals to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021
DEER PARK, Ill., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2021 financial and operating
Read more →ETONEton Pharmaceuticals Announces Acquisition of Approved Orphan Drug Product Carglumic Acid -Product is the first generic alternative to one of the highest priced pharmaceutical products in the world
Pharmaceuticals Announces Acquisition of Approved Orphan Drug Product Carglumic Acid is the first generic alternative to one of the highest priced pharmaceutical products in the world PARK, Ill. Oct. 28, 2021 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innov
Read more →ETONEton Pharmaceuticals Reports Second Quarter Financial Results
Pharmaceuticals Reports Second Quarter Financial Results PARK, Ill., Aug 16, 2021 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial r
Read more →ETONEton Pharmaceuticals to Report Second Quarter 2021 Financial Results on Monday, August 16, 2021
DEER PARK, Ill., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2021 financial and operatin
Read more →ETONEton Pharmaceuticals Acquires U.S. and Canadian Rights to ZENEO Hydrocortisone Autoinjector Expands Eton's Adrenal Insufficiency Orphan Drug Portfolio ZENEO Hydrocortisone is Expected to be the First and Only Hydrocortis
Pharmaceuticals Acquires U.S. and Canadian Rights to ZENEO Hydrocortisone Autoinjector Expands Eton's Adrenal Insufficiency Orphan Drug Portfolio ZENEO Hydrocortisone is Expected to be the First and Only Hydrocortisone Autoinjector for Patients Requiring Emergency Hydrocorti
Read more →ETONEton Pharmaceuticals Announces FDA Approval of Rezipres (Ephedrine Hydrochloride Injection)
Pharmaceuticals Announces FDA Approval of Rezipres (Ephedrine Hydrochloride Injection) PARK, Ill., June 15, 2021 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (Nasdaq: ETON) today announced that the U.S. Food and Drug Administration (FDA) has approved Rezipres (ephedrine hydroch
Read more →ETONEton Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Dehydrated Alcohol Injection
Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Dehydrated Alcohol Injection PARK, Ill., May 28, 2021 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (Nasdaq: ETON), today announced that the company has received a Complete Response Letter (CRL) from the U.S. Fo
Read more →ETONEton Pharmaceuticals Reports Record Revenue and Earnings - First quarter 2021 revenue of $11.9 million - First quarter 2021 operating earnings of $5.4 million; EPS of $0.19 - Eton now has three commercial, revenue-genera
Eton Pharmaceuticals Reports Record Revenue DEER PARK, Ill., May 13, 2021 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results
Read more →ETONEton Pharmaceuticals to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021
DEER PARK, Ill., May 04, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2021 financial and operating
Read more →ETONEton Pharmaceuticals Announces Appointment of Jenn Adams to its Board of Directors
Pharmaceuticals Announces Appointment of Jenn Adams to its Board of Directors PARK, Ill., March 17, 2021 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, tod
Read more →ETONEton Pharmaceuticals Announces Fourth Quarter and Full Year 2020 Financial Results
Pharmaceuticals Announces Fourth Quarter and Full Year 2020 Financial Results PARK, Ill., March 16, 2021 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, tod
Read more →ETONEton Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results on Tuesday, March 16, 2021
DEER PARK, Ill., March 04, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it will report fourth quarter and ful
Read more →ETONEton Pharmaceuticals to Participate in 10th Annual SVB Leerink Global Healthcare Conference
DEER PARK, Ill., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that company management will be participat
Read more →ETONEton Pharmaceuticals Announces Sale of Neurology Portfolio - Eton to receive up to $45 million plus royalties on product sales
Pharmaceuticals Announces Sale of Neurology Portfolio PARK, Ill., Feb. 8, 2021 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today ann
Read more →ETONEton Pharmaceuticals Announces Acquisition of Canadian Rights for
Pharmaceuticals Announces Acquisition of Canadian Rights for ALKINDI SPRINKLE PARK, Ill., Jan. 14, 2021 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pedi
Read more →ETONEton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Topiramate Oral Solution - Application Assigned a PDUFA Date of
Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Topiramate Oral Solution Application Assigned a PDUFA Date of August 6, 2021 PARK, Ill., December 17, 2020 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company
Read more →ETONEton Pharmaceuticals Announces Availability of Orphan Drug ALKINDI SPRINKLE (hydrocortisone) in the United States ALKINDI SPRINKLE is now exclusively available through AnovoRx Specialty Pharmacy. To support patient acces
Pharmaceuticals Announces Availability of Orphan Drug ALKINDI SPRINKLE (hydrocortisone) in the United States PARK, Ill., November 24, 2020 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing i
Read more →ETONEton Pharmaceuticals Announces Third Quarter 2020 Financial Results
DEER PARK, Ill., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today reported financial results for the third quarter ende
Read more →ETONEton Pharmaceuticals to Report Third Quarter Financial Results on Thursday, November 12, 2020
DEER PARK, Ill., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it will report third quarter 2020 fina
Read more →ETONEton Pharmaceuticals Announces Closing of Public Offering
Pharmaceuticals Announces Closing of Public Offering PARK, IL., October 16, 2020 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today an
Read more →ETONEton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Zonisamide Oral Suspension - Application Assigned a PDUFA Date of
Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Zonisamide Oral Suspension Application Assigned a PDUFA Date of May 29, 2021 PARK, Ill., October 15, 2020 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company
Read more →ETONEton Pharmaceuticals Prices Underwritten Public Offering of Common Stock
DEER PARK, Ill., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the pricing of an underwritten public offer
Read more →ETONEton Pharmaceuticals Announces Proposed Public Offering of Common Stock
Pharmaceuticals Announces Proposed Public Offering of Common Stock PARK, ILL., October 13, 2020 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric dis
Read more →ETONEton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Orphan Drug Dehydrated Alcohol Injection - Application Assigned a PDUFA Date of
Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Orphan Drug Dehydrated Alcohol Injection Assigned a PDUFA Date of May 27, 2021 Alcohol Injection Market Estimated to be Greater Than $100 Million Annually has Received Orphan Drug Designation for Metha
Read more →ETONEton Pharmaceuticals Submits New Drug Application to the FDA for Topiramate Oral Solution (ET-101) - Application Submitted for the Treatment of Partial-Onset Seizures and Migraine - Eton's Patent-Pending Product Addresse
Pharmaceuticals Submits New Drug Application to the FDA for Topiramate Oral Solution (ET-101) Application Submitted for the Treatment of Partial-Onset Seizures and Migraine Eton's Patent-Pending Product Addresses Significant Unmet Need for a Liquid Formulation of Topiramate To
Read more →ETONPharmaceuticals Announces FDA Approval of Orphan Drug ALKINDI SPRINKLE (hydrocortisone) as Replacement Therapy in Pediatric
Pharmaceuticals Announces FDA Approval of Orphan Drug ALKINDI SPRINKLE (hydrocortisone) as Replacement Therapy in Pediatric Patients with Adrenocortical Insufficiency SPRINKLE is the first and only FDA-approved granular hydrocortisone formulation for adrenocortical insufficienc
Read more →ETONEton Pharmaceuticals Announces FDA Approval of Orphan Drug ALKINDI SPRINKLE (hydrocortisone) as Replacement Therapy in Pediatric Patients with Adrenocortical Insufficiency
-ALKINDI SPRINKLE is the first and only FDA-approved granular hydrocortisone formulation for adrenocortical insufficiency specifically designed for children -Eton expects ALKINDI SPRINKLE to be available in the fourth quarter of 2020 DEER PARK, Ill., Sept. 29, 2020 (GLOBE NEWSW
Read more →ETONEton Investor and Media Contact: David Krempa dkrempa@etonpharma.com 612-387-3740 Bausch Health Investor Contact: Arthur Shannon arthur.shannon@bauschhealth.com (514) 856-855 (877) 281-6642 (toll free) Bausch Health Medi
APPROVES BAUSCH + LOMB ALAWAY PRESERVATIVE FREE (KETOTIFEN FUMARATE) OPHTHALMIC SOLUTION, 0.035% First OTC Preservative-Free Eye Drop Approved for the Treatment of Itchy Eyes Up to 12 Hours of Eye Itch Relief Quebec and DEER PARK, Ill., Sept. 25, 2020 - Bausch Health Companies
Read more →ETONEton Pharmaceuticals Provides Update on the FDA Review of EM-100
Pharmaceuticals Provides Update on the FDA Review of EM-100 PARK, Ill., Sept. 16, 2020 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, reported that its partner h
Read more →ETONEton Pharmaceuticals Announces Appointment of Ingrid Hoos as Senior Vice President of Scientific Affairs
Pharmaceuticals Announces Appointment of Ingrid Hoos as Senior Vice President of Scientific Affairs PARK, Ill., Aug 31, 2020 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative dru
Read more →ETONEton Pharmaceuticals Announces Second Quarter 2020 Financial Results
Pharmaceuticals Announces Second Quarter 2020 Financial Results DEER PARK, Ill., Aug 12, 2020 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today reported fina
Read more →ETONEton Pharmaceuticals to Report Second Quarter Financial Results on Wednesday, August 12, 2020
DEER PARK, Ill., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report second quarter 2020 financial and operating resu
Read more →ETONEton Pharmaceuticals Submits New Drug Application to the FDA for Zonisamide Oral Suspension (ET-104) - Application Submitted for the Treatment of Partial Seizures in Epilepsy Patients - Eton's Patent-Pending Product Addr
Pharmaceuticals Submits New Drug Application to the FDA for Zonisamide Oral Suspension (ET-104) Application Submitted for the Treatment of Partial Seizures in Epilepsy Patients Eton's Patent-Pending Product Addresses Significant Unmet Need for a Liquid Formulation of Zonisamide
Read more →ETONEton Pharmaceuticals Submits New Drug Application to the FDA for Orphan Drug Dehydrated Alcohol Injection (DS-100) -Granted Orphan Drug Designation by the FDA for the Treatment of Methanol Poisoning -Since the Start of C
Pharmaceuticals Submits New Drug Application to the FDA for Orphan Drug Dehydrated Alcohol Injection (DS-100) Orphan Drug Designation by the FDA for the Treatment of Methanol Poisoning the Start of COVID-19, the FDA has Recalled More Than 75 Contaminated Hand Sanitizers Due to
Read more →ETONEton Pharmaceuticals Announces First Quarter 2020 Financial Results
Pharmaceuticals Announces First Quarter 2020 Financial Results PARK, Ill., May 14, 2020 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today reported financial r
Read more →ETONEton Pharmaceuticals Confirms First-to-File Patent Challenge on Elcys (Cysteine Hydrochloride Injection) -Eton confirms first-to-file ANDA referencing Exela Pharma Sciences' Elcys product -Eton plans to file Post Grant R
Pharmaceuticals Confirms First-to-File Patent Challenge on Elcys (Cysteine Hydrochloride Injection) confirms first-to-file ANDA referencing Exela Pharma Sciences' Elcys product plans to file Post Grant Reviews in the U.S. Patent & Trademark Office challenging the validity of Ex
Read more →ETONEton Pharmaceuticals to Report First Quarter Financial Results on Thursday, May 14, 2020
DEER PARK, Ill., May 06, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report first quarter 2020 financial and operating result
Read more →ETONEton Pharmaceuticals Announces Appointment of Paul Stickler as Senior Vice President of Sales and Marketing Orphan Drug Expert Paul Stickler to Lead Eton's Commercialization of Alkindi Sprinkle and Pediatric Neurology Fr
Pharmaceuticals Announces Appointment of Paul Stickler as Senior Vice President of Sales and Marketing Drug Expert Paul Stickler to Lead Eton's Commercialization of Alkindi Sprinkle and Pediatric Neurology Franchise PARK, Ill., May 4, 2020 (GLOBE NEWSWIRE) - Eton Pharmaceutical
Read more →ETONEton Pharmaceuticals Announces Acquisition of U.S Marketing Rights to Pediatric Orphan Drug Alkindi Sprinkle -Estimated Market Opportunity of Greater than $100 Million -Alkindi Sprinkle NDA has been Assigned a
Pharmaceuticals Announces Acquisition of U.S Marketing Rights to Pediatric Orphan Drug Alkindi Sprinkle Market Opportunity of Greater than $100 Million Sprinkle NDA has been Assigned a September 29, 2020 Prescription Drug User Fee Act Date Sprinkle has been Granted Orphan Drug
Read more →ETONEton Pharmaceuticals Announces Acquisition of U.S Marketing Rights to Pediatric Orphan Drug Alkindi Sprinkle
-Estimated Market Opportunity of Greater than $100 Million -Alkindi Sprinkle NDA has been Assigned a September 29, 2020 Prescription Drug User Fee Act Date -Alkindi Sprinkle has been Granted Orphan Drug Designation for Adrenal Insufficiency in Pediatric Patients -Eton Executed
Read more →ETONEton Pharmaceuticals Reports Positive Study Results for ET-101 (Topiramate Oral Solution) -Results Demonstrated Bioequivalence to the Currently Approved Oral Solid Formulation -Market for Topiramate in Oral Form is Great
Pharmaceuticals Reports Positive Study Results for ET-101 (Topiramate Oral Solution) Demonstrated Bioequivalence to the Currently Approved Oral Solid Formulation for Topiramate in Oral Form is Greater than $800 million Annually PARK, Ill., March 17, 2020 (GLOBE NEWSWIRE) - Eto
Read more →ETONEton Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Financial Results
Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Financial Results PARK, Ill., Mar. 5, 2020 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today repor
Read more →ETONEton Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, March 5, 2020
DEER PARK, Ill., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report fourth quarter and full year 2019 financial and
Read more →ETONEton Pharmaceuticals Provides Update on ET-105 Program
Pharmaceuticals Provides Update on ET-105 Program PARK, Ill., February 19, 2020 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today provided an update on its ET
Read more →ETONEton Pharmaceuticals to Present at the 9th Annual SVB Leerink Healthcare Conference
DEER PARK, Ill., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Sean Brynjelsen, Chief Executive Officer, will present at the
Read more →ETONEton Pharmaceuticals and Xellia Pharmaceuticals Announce Biorphen (phenylephrine HCl) Co-Promotion Agreement - Xellia's U.S.- Based Hospital Sales Force Will Immediately Begin Promoting Biorphen in Collaboration with Eto
Pharmaceuticals and Xellia Pharmaceuticals Announce Biorphen (phenylephrine HCl) Co-Promotion Agreement - Xellia's U.S.- Based Hospital Sales Force Will Immediately Begin Promoting Biorphen in Collaboration with Eton - Agreement Significantly Expands Biorphen Commercial Footpr
Read more →ETONEton Pharmaceuticals Announces Commercial Availability of Biorphen (phenylephrine HCI) Injection ~ Biorphen is the First and Only Ready-to-Use FDA-Approved Injectable Formulation of Phenylephrine ~ ~ Biorphen is Now Avai
Pharmaceuticals Announces Commercial Availability of Biorphen (phenylephrine HCI) Injection Biorphen is the First and Only Ready-to-Use FDA-Approved Injectable Formulation of Phenylephrine ~ Biorphen is Now Available for Order Through Major Wholesalers ~ Biorphen is Eton Pharm
Read more →ETONEton Pharmaceuticals Announces Third Quarter Financial Results and Highlights Business Progress - Biorphen Expected to Launch by End of November - Company to Host Conference Call and Webcast Today at 4:30 p.m. ET (3:30 p
Pharmaceuticals Announces Third Quarter Financial Results and Highlights Business Progress - Biorphen Expected to Launch by End of November - Company to Host Conference Call and Webcast Today at 4:30 p.m. ET (3:30 p.m. CT) PARK, Ill. Nov 14, 2019 (GLOBE NEWSWIRE) - Eton Pharm
Read more →ETONEton Pharmaceuticals Announces $10 Million Debt Facility with SWK Holdings
DEER PARK, Ill., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced it has entered into a $10 million debt facility with SWK Holdings Co
Read more →ETONEton Pharmaceuticals to Report Third Quarter 2019 Financial Results on Thursday, November 14, 2019
DEER PARK, Ill., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report third quarter 2019 financial and operating resul
Read more →ETONEton Pharmaceuticals Announces U.S. FDA Approval of Biorphen (phenylephrine HCI) Injection Biorphen is the First and Only Ready-to-Use FDA-Approved Injectable Formulation of Phenylephrine Biorphen Eliminates Need for Com
Pharmaceuticals Announces U.S. FDA Approval of Biorphen (phenylephrine HCI) Injection is the First and Only Ready-to-Use FDA-Approved Injectable Formulation of Phenylephrine Eliminates Need for Compounding, Reducing Risks for Unsafe Injection Practices, Medication Administratio
Read more →ETONEton Pharmaceuticals to Participate in Lake Street 3rd Annual Best Ideas Growth Conference
DEER PARK, Ill., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Sean Brynjelsen, Chief Executive Officer, will participate in
Read more →ETONEton Pharmaceuticals Announces Positive Results from Clinical Study Report of ET-104 ET-104 Successfully Demonstrated Bioequivalence to Currently Approved Oral Solid Formulation New Drug Application (NDA) Submission Expe
Pharmaceuticals Announces Positive Results from Clinical Study Report of ET-104 Successfully Demonstrated Bioequivalence to Currently Approved Oral Solid Formulation Drug Application (NDA) Submission Expected in Fourth Quarter of 2019 PARK, Ill., August 19, 2019 (BUSINESSWIRE)
Read more →ETONEton Announces Second Quarter Financial Results and Highlights Business Progress - ET-203 NDA submitted, Three Additional Product Submissions Expected in 2019 - ET-105 Acquisition Closed & Application Assigned PDUFA Date
Announces Second Quarter Financial Results and Highlights Business Progress - ET-203 NDA submitted, Three Additional Product Submissions Expected in 2019 - ET-105 Acquisition Closed & Application Assigned PDUFA Date of March 17, 2020 - Company to Host Conference Call and Webc
Read more →ETONEton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-105 -ET-105 assigned Prescription Drug User Fee Act (PDUFA) target action date of
Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-105 assigned Prescription Drug User Fee Act (PDUFA) target action date of March 17, 2020 PARK, Ill., August 1, 2019 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical co
Read more →ETONEton Pharmaceuticals to Report Second Quarter 2019 Financial Results on Tuesday, August 6, 2019
DEER PARK, Ill., July 30, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report second quarter 2019 financial and operating resu
Read more →ETONEton Pharmaceuticals Provides Update on EM-100 Program
Pharmaceuticals Provides Update on EM-100 Program PARK, ILL., July 12, 2019 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that the U.S Food and
Read more →ETONEton Pharmaceuticals Announces Licensing of Lamotrigine New Drug Application and Provides Pipeline Update - Unique patent-pending formulation of lamotrigine addresses significant unmet need in pediatric epilepsy patients
Pharmaceuticals Announces Licensing of Lamotrigine New Drug Application and Provides Pipeline Update Unique patent-pending formulation of lamotrigine addresses significant unmet need in pediatric epilepsy patients NDA was submitted in May 2019; product launch anticipated in 1H
Read more →ETONEton Pharmaceuticals to Present at 20th Annual B. Riley FBR Investor Conference
DEER PARK, Ill., May 15, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Sean Brynjelsen, Chief Executive Officer, will present at the 2
Read more →ETONEton Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Business Progress - Four Products Currently Under Review with the FDA - - Expecting Multiple Product Launches in Second Half of 2019 - - Co
Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Business Progress - Four Products Currently Under Review with the FDA - - Expecting Multiple Product Launches in Second Half of 2019 - - Company to Host Conference Call and Webcast today at 4:30 p.m. E
Read more →ETONEton Pharmaceuticals to Report First Quarter 2019 Financial Results on Tuesday, May 7, 2019
DEER PARK, Ill., April 30, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report first quarter 2019 financial and operating res
Read more →ETONEton Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Business Progress - NDA filing for ET-202 Accepted for Review and Assigned PDUFA Date of
Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Business Progress NDA filing for ET-202 Accepted for Review and Assigned PDUFA Date of October 21, 2019 - PARK, III., Mar. 25, 2019 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc. (NASDAQ:
Read more →ETONEton Pharmaceuticals Submits New Drug Application for DS-200
DEER PARK, Ill., March 14, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), today announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for DS-200 via the Rolling Review process. DS-200 was previous
Read more →ETONEton Pharmaceuticals to Present at the 8th Annual SVB Leerink Healthcare Conference
DEER PARK, Ill., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Sean Brynjelsen, Chief Executive Officer, will participate in
Read more →ETONEton Pharmaceuticals Enters Into License Agreement for Two Branded Hospital Product Candidates
Transaction adds an additional potential 2019 product launch to Eton’s pipeline ET-202 NDA was submitted in December 2018; PDUFA date expected to be in Q4 2019 ET-203 NDA expected to be submitted by Q3 2019 DEER PARK, Ill., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceutical
Read more →ETONEton Pharmaceuticals Announces Licensing of Oral Liquid Product Candidate ET-104
DEER PARK, Ill., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it has entered into a licensing and supply agreement for ET-10
Read more →ETONEton Pharmaceuticals Reports Third Quarter Results and Business Update
Licensed High-Value Injectable Product Candidate Successfully Completed Initial Public Offering DEER PARK, Ill., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative
Read more →ETONEton Pharmaceuticals Announces Pricing of Initial Public Offering
DEER PARK, Ill., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced the pricing of its initial public offering of 3,600,000 shares of it
Read more →Competitive Position
How ETON ranks across every disease it competes inCompetitive Position is a premium feature
See how ETON ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial